PMID- 8639311
OWN - NLM
STAT- MEDLINE
DCOM- 19960712
LR  - 20190905
IS  - 0284-186X (Print)
IS  - 0284-186X (Linking)
VI  - 35
IP  - 2
DP  - 1996
TI  - Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for 
      non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma 
      Study Group.
PG  - 165-70
AB  - One hundred and two patients with recurrent or refractory non-Hodgkin's lymphoma 
      (NHL) were treated with MIME (methyl-GAG, ifosfamide, methotrexate, etoposide) in 
      accordance with a prospective protocol. Of 75 patients with high-grade malignant 
      NHL (median age 57 years, range 21-79), 15 patients (20%) obtained a complete 
      response (CR) and 27 patients (36%) a partial remission (PR), giving an overall 
      response rate of 56%. The remissions were usually short when not consolidated 
      with ABMT or radiotherapy. The probability of progression-free survival after 2 
      years was 13%, and the cause-specific survival was 23%. Of 27 patients with 
      low-grade NHL (median age 46 years, range 37-86), 7% had a CR and 37% a PR giving 
      a response rate of 44%. The remissions were again usually short when not 
      consolidated, and the probability of progression-free survival at two years was 
      11%, and the cause-specific survival 26%. The main toxicity was hematological 
      with septicemia in 20% of the patients and other severe infections in 19%. 
      Fifteen patients (11 high-grade NHL and 4 low-grade NHL) were consolidated with 
      high-dose therapy followed by ABMT, of whom 6 are in continuous CR. We conclude 
      that MIME can induce remissions in NHL patients, and that the remission rates are 
      comparable with those of many other salvage regimens. The remissions are, 
      however, generally of short duration and need consolidation. There was 
      considerable toxicity therefore patients not suitable for ABMT preferably should 
      be treated with less toxic salvage regimens.
FAU - Enblad, G
AU  - Enblad G
AD  - Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden.
FAU - Hagberg, H
AU  - Hagberg H
FAU - Glimelius, B
AU  - Glimelius B
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - OD5Q0L447W (Mitoguazone)
RN  - UM20QQM95Y (Ifosfamide)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - MIME protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Bone Marrow Transplantation
MH  - Combined Modality Therapy
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Humans
MH  - Ifosfamide/administration & dosage
MH  - Lymphoma, Non-Hodgkin/*drug therapy/therapy
MH  - Male
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Mitoguazone/administration & dosage
MH  - Prospective Studies
MH  - Salvage Therapy
MH  - Sweden
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.3109/02841869609098497 [doi]
PST - ppublish
SO  - Acta Oncol. 1996;35(2):165-70. doi: 10.3109/02841869609098497.